Business Wire

SoftServe Releases 2021 Sustainability Report

14.9.2022 16:02:00 EEST | Business Wire | Press release

Share

SoftServe, a leading digital authority and consulting company, has released the company’s sustainability report for 2021. Prepared in accordance with GRI standards, the report highlights SoftServe’s commitment to sustainability practices as a dedicated member of the United Nations Global Compact. The report provides an overview of the company’s corporate social responsibility (CSR) initiatives, including governance of CSR, IT education, environmental management, and progress in diversity, equity, and inclusion (DE&I).

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220830005028/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Report demonstrates the company’s commitment to sustainability practices and obligations as a member of the United Nations Global Compact. (Photo: Business Wire)

“SoftServe’s mission is to empower talented people to change the world,” said Chris Baker, CEO. “We stay committed to that mission by making our clients successful, developing our teams and ourselves while innovating every day. This Sustainability Report reflects our ongoing commitment to bringing a sustainable future to our clients, associates, and communities.”

Governance of CSR

SoftServe maintains five cross-functional sustainability councils overseeing individual CSR initiatives. Each council consists of contributors from specific business groups and is overseen by a chairperson and an executive sponsor to ensure effective decision-making processes. As many as 70 leaders throughout the organization are engaged in councils and contribute their efforts to building sustainable practices and scaling impact across the business.

IT Education

IT education and training for qualified specialists remains one of the key areas of corporate social responsibility of the company. SoftServe collaborates with 64 universities around the world, and in 2021 alone, introduced four undergraduate programs with a dual form of education combining theoretical classes with corporate practice.

SoftServe University, which celebrated its 15th anniversary last year, is developing a variety of solutions for both in-house training and for those looking to start an IT career. Out of 2,282 SoftServe IT Academy interns in 2021, most secured a new career with SoftServe - 120% more than a year earlier.

Environment

Last year, SoftServe reduced the number of direct emissions from the production of goods by 55.4% compared to the previous year. The company also introduced a new approach to environmental management and set ambitious environmental goals by 2031. These goals include becoming a zero-carbon business, achieving zero waste, designing environmentally sustainable offices, and developing IT solutions to help meet environmental challenges.

Diversity, Equity, and Inclusion

Principles of diversity, equity, and inclusion drive a culture at SoftServe where every associate has the same opportunity for growth and advancement. The company’s special Diversity, Equity & Inclusion Council works to adhere to these principles and promotes constant progress through operational action.

In addition, SoftServe is a globally responsible employer striving to make each associate’s learning journey as inclusive as possible. Over the last two years, and throughout rapid corporate expansion, SoftServe prioritized accessible office construction and inclusive learning design, and a recent accessibility audit shows an 18% increase in entirely accessible offices.

Click here for more information on SoftServe’s sustainability report.

About SoftServe

SoftServe is a digital authority that advises and provides at the cutting-edge of technology. We reveal, transform, accelerate, and optimize how enterprises and software companies do business. Our end-to-end solutions and expertise deliver innovation, quality, and speed across the healthcare, retail, energy, manufacturing, and financial services verticals. We empower enterprises and software companies to (re)identify differentiation, accelerate solution development, and vigorously compete in today’s marketplace—no matter where you are in your journey.

Visit our website, blog, LinkedIn, Facebook, and Twitter.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Andrew Kavka
Analyst and Public Relations Lead
akavk@softserveinc.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Rapid Medical™’s TIGERTRIEVER™ 13 Demonstrates Promising 90-Day Outcomes in DISTALS Trial, Reinforcing Pivotal Safety and Efficacy Findings7.5.2026 15:03:00 EEST | Press release

Rapid Medical™, a leading developer of advanced stroke treatment devices, today announced full results from the DISTALS randomized clinical trial, presented at the 11th European Stroke Organisation Conference (ESOC) in Maastricht, Netherlands, showing that TIGERTRIEVER™ 13 can safely restore blood flow to the brain and may improve clinical outcomes in patients with distal and medium vessel occlusion (DMVO) stroke. These findings build on earlier results showing a threefold improvement in restoring blood flow compared with medical management alone (p<0.0001), with no cases of serious brain bleeding observed in the treatment group. “These results show we can now safely restore blood flow and suggest this will make a meaningful difference for the right patients,” said Jeffrey L. Saver, MD, UCLA, and Principal Investigator of DISTALS. “What’s important is that both the device and the trial were designed specifically for distal stroke. By using a device built for these small vessels and mea

2 Million Downloads in Six Months: Tabelog’s Multilingual App Solves Critical Dining Pain Points for Travelers to Japan7.5.2026 15:00:00 EEST | Press release

Tabelog (https://tabelog.com/en/), one of Japan’s largest (*1) restaurant search and reservation services operated by Kakaku.com, Inc., has announced that its multilingual smartphone app (iOS/Android) for travelers visiting Japan has reached 2 million downloads (*2). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260507560248/en/ 2M+ Downloads in 6 Months. The app also ranked #1 in downloads among Restaurant Search Apps in Japan for International Travelers (*3) in Taiwan, Hong Kong, South Korea, and the U.S., reflecting its immense popularity among global visitors. Download URL: https://tabelog-tourists.onelink.me/3eEh/iqkkho9r The Trusted Choice for Global Travelers: Solving Two Major Dining Pain Points in Japan For years, international visitors to Japan have faced two critical dining pain points: [Pain Point 1] The Information Gap: Most available resources are tailored for tourists, making it difficult to find the true loc

Altasciences and Certara Announce Strategic Partnership to Accelerate Early Drug Development7.5.2026 15:00:00 EEST | Press release

Altasciences, a fully integrated drug development solution company, andCertara (Nasdaq: CERT), a global leader in model-informed drug development (MIDD), today announced a strategic partnership to accelerate early-phase development programs. Fewer than half of preclinical drug candidates successfully reach first-in-human trials. Failures are driven by toxicity, poor pharmacokinetics, lack of efficacy, and challenges translating results from animals to humans. Many of these risks can be mitigated through a fully integrated model-informed drug development approach. Building on Altasciences’ Acceleration Platform, the integration of Certara’s strategic drug development services and biosimulation technology enables sponsors to establish proof of mechanism earlier, design more efficient studies, and make informed go/no-go decisions with greater confidence. By embedding modeling insights and digital workflows directly into development execution, study designs are optimized, dosing strategies

FIFA and Fanatics Expand Wide-Ranging Relationship to Include Historic Exclusive Collectibles Agreement (Trading Cards, Stickers and Trading Card Games)7.5.2026 14:00:00 EEST | Press release

In a landmark agreement expanding their already successful wide-ranging commercial relationship, FIFA and Fanatics have signed a long-term, exclusive collectibles licensing deal that features trading cards, stickers, and trading card games. The agreement, which will begin in full in 2031, covers both physical and digital collectibles. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260507105628/en/ An example of the product innovations that will be brought to fans under this new partnership is the highly sought-after player jersey patch program, including debut patches, which will be inserted into football trading cards from 2031 onward. All products will be designed and developed through Fanatics Collectibles and produced under the Topps brand. As a part of the deal, Fanatics will bring the magic to young people in every region of the world and support youth football globally by distributing more than $150 million in collect

DEFINITIVE Trial Reaches Major Milestone: All Centres Approved and More Than 50% Recruitment Achieved7.5.2026 12:21:00 EEST | Press release

The DEFINITIVE project, a landmark European Union-funded international phase III clinical trial evaluating the use of the HER2DX diagnostic assay to guide personalised treatment in early-stage HER2-positive breast cancer (BC), announces two major operational milestones at the ESMO Breast Cancer 2026 congress. Approvals have been obtained in the 7 participating countries, 33 clinicals sites are now open for patient recruitment. The trial has reached over 50% of its recruitment target, marking a pivotal moment on the path toward to transforming HER2-positive BC treatment. About the DEFINITIVE Project The DEFINITIVE project is a 5-year, prospective, open-label, randomised, two-arm phase III international clinical trial conducted across 44 centres in 7 European member states and associated countries. The trial aims to demonstrate that personalising treatment decisions for patients with early-stage (stage II to IIIA) HER2-positive BC using the HER2DX genomic diagnostic assay can improve pat

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye